These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26125152)

  • 1. Meta-analysis of osteoporosis: fracture risks, medication and treatment.
    Liu W; Yang LH; Kong XC; An LK; Wang R
    Minerva Med; 2015 Aug; 106(4):203-14. PubMed ID: 26125152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
    Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
    Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world challenges of treating osteoporosis.
    Owens G
    Am J Manag Care; 2011 May; 17 Suppl 6():S177-84. PubMed ID: 21882487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of fractures and compliance to treatment in osteoporosis.
    Trevisan C
    Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):22-4. PubMed ID: 21970911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of osteoporotic fracture risk with medication nonadherence.
    Ross S; Samuels E; Gairy K; Iqbal S; Badamgarav E; Siris E
    Value Health; 2011 Jun; 14(4):571-81. PubMed ID: 21669382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
    Col NF; Bowlby LA; McGarry K
    Minerva Med; 2005 Oct; 96(5):331-42. PubMed ID: 16227948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.
    Montori VM; Shah ND; Pencille LJ; Branda ME; Van Houten HK; Swiglo BA; Kesman RL; Tulledge-Scheitel SM; Jaeger TM; Johnson RE; Bartel GA; Melton LJ; Wermers RA
    Am J Med; 2011 Jun; 124(6):549-56. PubMed ID: 21605732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations on the management of fragility fracture risk in women younger than 70 years.
    Palacios S; Christiansen C; Sánchez Borrego R; Gambacciani M; Hadji P; Karsdal M; Lambrinoudaki I; Lello S; O'Beirne B; Romao F; Rozenberg S; Stevenson JC; Ben-Rafael Z
    Gynecol Endocrinol; 2012 Oct; 28(10):770-86. PubMed ID: 22558997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
    Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
    Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for osteoporosis.
    Croswell J
    Am Fam Physician; 2011 May; 83(10):1201-2. PubMed ID: 21568255
    [No Abstract]   [Full Text] [Related]  

  • 19. Current treatment approaches to osteoporosis - 2013.
    Honig S; Rajapakse CS; Chang G
    Bull Hosp Jt Dis (2013); 2013; 71(3):184-8. PubMed ID: 24151942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis.
    Ensrud KE; Crandall CJ
    Ann Intern Med; 2017 Aug; 167(3):ITC17-ITC32. PubMed ID: 28761958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.